Ginkgo Bioworks Holdings Inc (DNA)
0.9241
0.00 (0.00%)
USD |
NYSE |
Apr 19, 10:17
Ginkgo Bioworks Holdings Cash from Operations (TTM): -295.50M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -295.50M |
| September 30, 2023 | -342.20M |
| June 30, 2023 | -297.01M |
| March 31, 2023 | -322.88M |
| December 31, 2022 | -252.20M |
| Date | Value |
|---|---|
| September 30, 2022 | -313.21M |
| June 30, 2022 | -290.08M |
| March 31, 2022 | -225.58M |
| December 31, 2021 | -253.82M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-342.20M
Minimum
Sep 2023
-225.58M
Maximum
Mar 2022
-288.05M
Average
-295.50M
Median
Dec 2023
Cash from Operations (TTM) Benchmarks
| Agenus Inc | -224.20M |
| Illumina Inc | 478.00M |
| Teladoc Health Inc | 350.02M |
| Sarepta Therapeutics Inc | -500.99M |
| Ultragenyx Pharmaceutical Inc | -474.81M |